Current and Emerging Therapies for COVID-19 in Lung Transplantation.

IF 1.1 Q4 RESPIRATORY SYSTEM

Current pulmonology reports Pub Date : 2023-01-01 DOI:10.1007/s13665-023-00302-3

Daniel Z P Friedman, Natasha N Pettit, Erica MacKenzie, Jennifer Pisano

{"title":"Current and Emerging Therapies for COVID-19 in Lung Transplantation.","authors":"Daniel Z P Friedman, Natasha N Pettit, Erica MacKenzie, Jennifer Pisano","doi":"10.1007/s13665-023-00302-3","DOIUrl":null,"url":null,"abstract":"Purpose of review: The landscape of the coronavirus disease 2019 (COVID-19) pandemic has rapidly changed over the past 3 years. Paralleling this evolution, the scientific and medical communities have reported many novel findings relating to the infection's epidemiology, transmission, diagnosis, and treatment. We review pertinent studies of COVID-19 therapeutics with an emphasis on their application to lung transplant recipients.Recent findings: Agents that have been well-studied for treating COVID-19 include antivirals (remdesivir, nirmatrelvir/ritonavir, molnupiravir), monoclonal antibodies, and immunomodulators (for example, corticosteroids and tocilizumab).Summary: Remdesivir remains an essential therapy for managing mild-moderate COVID-19. Though highly efficacious for mild-moderate COVID-19 for outpatient therapy, ritonavir-boosted nirmatrelvir has limited use in lung transplant recipients due to significant drug-drug interactions. Monoclonal antibodies, though useful, are the most affected by the emergence of new viral variants.","PeriodicalId":72745,"journal":{"name":"Current pulmonology reports","volume":null,"pages":null},"PeriodicalIF":1.1000,"publicationDate":"2023-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9932416/pdf/","citationCount":"1","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Current pulmonology reports","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.1007/s13665-023-00302-3","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q4","JCRName":"RESPIRATORY SYSTEM","Score":null,"Total":0}

引用次数: 1

Abstract

Purpose of review: The landscape of the coronavirus disease 2019 (COVID-19) pandemic has rapidly changed over the past 3 years. Paralleling this evolution, the scientific and medical communities have reported many novel findings relating to the infection's epidemiology, transmission, diagnosis, and treatment. We review pertinent studies of COVID-19 therapeutics with an emphasis on their application to lung transplant recipients.

Recent findings: Agents that have been well-studied for treating COVID-19 include antivirals (remdesivir, nirmatrelvir/ritonavir, molnupiravir), monoclonal antibodies, and immunomodulators (for example, corticosteroids and tocilizumab).

Summary: Remdesivir remains an essential therapy for managing mild-moderate COVID-19. Though highly efficacious for mild-moderate COVID-19 for outpatient therapy, ritonavir-boosted nirmatrelvir has limited use in lung transplant recipients due to significant drug-drug interactions. Monoclonal antibodies, though useful, are the most affected by the emergence of new viral variants.

Abstract Image

查看原文本刊更多论文

肺移植中当前和新兴的COVID-19治疗方法。

回顾目的:在过去三年中，2019冠状病毒病(COVID-19)大流行的形势发生了迅速变化。与此同时，科学界和医学界报告了许多与感染的流行病学、传播、诊断和治疗有关的新发现。我们回顾了COVID-19治疗方法的相关研究，重点是它们在肺移植受体中的应用。最近的发现:已被充分研究用于治疗COVID-19的药物包括抗病毒药物(remdesivir、nirmatrelvir/ritonavir、molnupiravir)、单克隆抗体和免疫调节剂(例如，皮质类固醇和托珠单抗)。总结:瑞德西韦仍然是治疗轻中度COVID-19的基本疗法。尽管在门诊治疗中对轻中度COVID-19非常有效，但利托那韦增强的nirmatrelvir在肺移植受者中的应用有限，因为药物-药物相互作用明显。单克隆抗体虽然有用，但受新病毒变体出现的影响最大。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

Current pulmonology reports

自引率

0.00%

发文量